- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey -

- Pooled analysis of three prospective Phase I/II studies in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates encouraging median overall survival (mOS) across chemotherapy-naive, second-line, and heavily pretreated patient populations -

- Patients treated with Alpha DaRT after 1st line chemotherapy reached median overall survival (mOS) of 11.2 and 11.1 months in metastatic and locally advanced disease, respectively, from the date of trial enrollment, compared to ~4 - 6 months for metastatic patients and ~ 9 months for locally advanced patients with second-line chemotherapy, based on published historical data -

- Favorable safety profile observed across the Alpha DaRT trials, with treatment-associated adverse events reported in 36% of subjects and Grade ≥3 events in 9%, with no treatment-related deaths and no chronic toxicity; all Grade ≥3 events resolved -

- Following these strong survival data, Company next turns to anticipated completion of recruitment in the multicenter U.S. IMPACT pancreatic cancer trial, which is exploring the ability of Alpha DaRT, in combination with initiation of front-line chemotherapy, to deliver a potent and focused local dose without exacerbating the harsh systemic side effects of standard chemotherapy -

JERUSALEM, June 01, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW))) ("Alpha Tau", or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced positive overall survival and safety results from a pooled analysis of three prospective Phase I/II clinical studies evaluating endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The results were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Pancreatic cancer remains one of the most lethal of all solid tumors, with a five-year survival rate of less than 10% and survival often measured in only months for patients with advanced disease. Treatment options are particularly limited for patients who are ineligible for chemotherapy or who have progressed through one or more lines of systemic therapy, where historical survival is consistently poor and few effective interventions exist.

The pooled, ad-hoc analysis combined safety and efficacy data from three studies, conducted at the Jewish General Hospital, at the Centre Hospitalier de l'Université de Montréal (CHUM) in Montreal, Canada, and at the Hadassah Medical Center in Jerusalem, Israel. The analysis included all patients who received the intended Alpha DaRT treatment, with a range of patients having undergone varying lines of prior chemotherapy. Survival was analyzed using the Kaplan-Meier method and assessed by disease stage (locally advanced versus metastatic) and by number of prior chemotherapy lines (zero, one, or two).